A Compassionate Access Protocol For Those Patients Who Have Completed A4001029

• Status: No longer available
• Trial end date: 2011-07-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a compassionate study to provide continued access to maraviroc for only those subjects completing study A4001029 who are showing clinical benefit. Assessments of safety and tolerability of maraviroc when added to OBT will be continued.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: ViiV Healthcare
• Collaborator: Pfizer
• Treatments: Maraviroc

Criteria

Inclusion Criteria:

• Patients having completed study A4001029 in Canada and still deriving clinical benefit.

Exclusion Criteria:

• None